Literature DB >> 22153829

Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung.

Tetsuhiko Taira1, Genichiro Ishii, Kanji Nagai, Kiyotaka Yoh, Yusuke Takahashi, Yuki Matsumura, Motohiro Kojima, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Hiroshi Takashima, Hiromasa Inoue, Yuichiro Ohe, Atsushi Ochiai.   

Abstract

Tumor budding is morphologically defined as infiltration by small clusters of cancer cells. While the biological properties of budding cells in adenocarcinoma (decreased expression of adhesion molecules and of differentiation markers) have been elucidated, those of the cells in squamous cell carcinoma (SqCC) of the lung still remain to be clarified. We examined the clinicopathological data of 217 patients with SqCC of the lung. Furthermore we evaluated the immunohistochemical properties of the budding cells. Tumor budding was observed in 83 (38.2%) patients. A statistically significant difference was observed in overall 5-year survival rates between the cases showing tumor budding and the cases not showing budding (45.6% vs. 64.0%, p<0.001). As compared with cancer cells forming solid nests, budding cells (BCs) exhibited reduced expression levels of the cellular adhesion molecules (E-cadherin; p=0.004, β-catenin; p=0.002) and increased expression levels of laminin-5γ2 (p=0.001). On the other hand, no significant differences in the staining scores for differentiation markers (p63 and podoplanin) were found between BCs and cancer cells forming nests. Multivariate analysis revealed that tumor budding was a significant independent prognostic factor in patients with SqCC of the lung (p=0.022). Tumor budding is an independent adverse prognostic factor in patients with SqCC of the lung. Although budding cells in SqCC exhibited reduced expression levels of the cellular adhesion molecules, the expression levels of specific differentiation markers were retained, suggesting that the budding mechanism in SqCC may differ, at least in part, from that in adenocarcinoma.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22153829     DOI: 10.1016/j.lungcan.2011.11.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  18 in total

1.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

2.  Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope?

Authors:  Fabio Grizzi; Giuseppe Celesti; Gianluca Basso; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 3.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

4.  Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Nishant Thakur; Muhammad Joan Ailia; Yosep Chong; Ok Ran Shin; Kwangil Yim
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

5.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Authors:  Shaohua Lu; Kay See Tan; Kyuichi Kadota; Takashi Eguchi; Sarina Bains; Natasha Rekhtman; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2016-09-28       Impact factor: 15.609

6.  Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Kaitlin M Woo; Camelia S Sima; David J Finley; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

7.  Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer.

Authors:  Hongxia Hao; Zhiguo Zhou; Shulong Li; Genevieve Maquilan; Michael R Folkert; Puneeth Iyengar; Kenneth D Westover; Kevin Albuquerque; Fang Liu; Hak Choy; Robert Timmerman; Lin Yang; Jing Wang
Journal:  Phys Med Biol       Date:  2018-05-02       Impact factor: 3.609

8.  Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding.

Authors:  Yaju Feng; Lumeng Wang; Ting Wang; Ying Li; Qingqing Xun; Renya Zhang; Lin Liu; Lei Li; Wei Wang; Yixuan Tian; Lili Yang; Xiao Zhi; Bijiao Zhou; Xin Chen; Tao Sun; Yanrong Liu
Journal:  Mol Ther       Date:  2021-02-10       Impact factor: 12.910

Review 9.  Tumor Budding: The Name is EMT. Partial EMT.

Authors:  Alexandru Dan Grigore; Mohit Kumar Jolly; Dongya Jia; Mary C Farach-Carson; Herbert Levine
Journal:  J Clin Med       Date:  2016-04-29       Impact factor: 4.241

10.  The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer.

Authors:  F J A Gujam; D C McMillan; Z M A Mohammed; J Edwards; J J Going
Journal:  Br J Cancer       Date:  2015-08-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.